Drug Profile
ACT 389949
Alternative Names: ACT-389949Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Class Anti-inflammatories; Antidementias
- Mechanism of Action FPR2 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 01 May 2013 Actelion completes a phase I trial in Healthy volunteers in the UK (NCT02099201)
- 01 Nov 2012 Phase-I clinical trials in Metabolic disorders (in volunteers) in United Kingdom (PO)
- 01 May 2012 Actelion completes a phase I trial in Healthy volunteers in the Netherlands (NCT02099071)